[Joanne S]

DUKE CONCLUSION: Although this was a small pilot study, the well-tolerated nature of the vaccines, the lack of cardiac toxicity, significant immunogenicity, and a 100% 4.5-year survival rate suggest that vaccination with HER2 ICD protein-containing DC is appropriate for further study in this population.

I agree with you, the review I posted was published before the findings of the Duke Study. Although the Duke Study produced excellent and VERY promising results (per above DUKE CONCLUSION), the responses to your post suggest that these ladies seem anxious for immediate inquiry to their physicians when it is so very far from being available---just wanted to clarify to avoid possible misunderstanding. I hope this helps to clarify.

I am neither a doctor nor nurse so usually I'm lucky if I understand half of what I read on trials, reviews, findings... so I'm not sure if the following is exactly the same as the dendritic cell vaccine; if you and anyone else interested in checking, there are studies for NEUVENGE for HER2 breast cancer---it is similar or possibly the same as PROVENGE for prostate cancer which came very, very close to being approved earlier this year by the FDA.

Best to you.